Literature DB >> 17156861

Real-time PCR determination of human herpesvirus 6 antiviral drug susceptibility.

Yuji Isegawa1, Masaya Takemoto, Koichi Yamanishi, Atsushi Ohshima, Nakaba Sugimoto.   

Abstract

A quantitative real-time PCR assay was developed to determine the antiviral drug susceptibility of human herpesvirus 6 (HHV-6). After short-term culture of the virus, HHV-6 isolates' susceptibility to the antiviral ganciclovir (GCV) was determined by measuring the HHV-6 variant B (HHV-6B) DNA levels in culture supernatants and infected cells using real-time PCR. A total of 12 well-characterized GCV-sensitive or -resistant strains and clinical isolates were used. This new assay with real-time PCR readout permitted the rapid (3 days), objective, and reproducible determination of HHV-6 drug susceptibilities with no need for stringent control of the initial multiplicity of infection. Furthermore, the real-time PCR assay results showed good correlation (rs=0.95) with those from the conventional TCID50 (50% tissue culture infecting dose) reduction assay (TRA). Thus, the real-time PCR assay described in this report was found to be a suitable quantitative method for determining the susceptibility of HHV-6 to antiviral drugs. It is faster and simpler than the TRA, and it is amenable to use in the routine diagnostic virology laboratory.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17156861     DOI: 10.1016/j.jviromet.2006.10.009

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  Viral drug sensitivity testing using quantitative PCR: effect of tyrosine kinase inhibitors on polyomavirus BK replication.

Authors:  Parmjeet S Randhawa; Noush A Farasati; Yuchen Huang; Markus Y Mapara; Ron Shapiro
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

2.  Evaluation of Epstein-Barr virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Lotfi Bounaadja; Jocelyne Piret; Nathalie Goyette; Guy Boivin
Journal:  J Clin Microbiol       Date:  2013-01-16       Impact factor: 5.948

3.  Calibration technologies for correct determination of Epstein-Barr Virus, human herpesvirus 6 (HHV-6), and HHV-8 antiviral drug susceptibilities by use of real-time-PCR-based assays.

Authors:  Francesco Broccolo; Paolo Lusso; Mauro Malnati
Journal:  J Clin Microbiol       Date:  2013-06       Impact factor: 5.948

4.  The U95 protein of human herpesvirus 6B interacts with human GRIM-19: silencing of U95 expression reduces viral load and abrogates loss of mitochondrial membrane potential.

Authors:  W M Yeo; Yuji Isegawa; Vincent T K Chow
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

5.  Characterization of the human herpesvirus 6 U69 gene product and identification of its nuclear localization signal.

Authors:  Yuji Isegawa; Yoichi Miyamoto; Yoshinari Yasuda; Katsunori Semi; Kenji Tsujimura; Rikiro Fukunaga; Atsushi Ohshima; Yasuhiro Horiguchi; Yoshihiro Yoneda; Nakaba Sugimoto
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

6.  Optimisation of a quantitative polymerase chain reaction-based strategy for the detection and quantification of human herpesvirus 6 DNA in patients undergoing allogeneic haematopoietic stem cell transplantation.

Authors:  Miriam Y H Ueda; Paulo G Alvarenga; Juliana M Real; Eloisa de Sá Moreira; Aripuanã Watanabe; Ana Maria Passos-Castilho; Matheus Vescovi; Yana Novis; Vanderson Rocha; Adriana Seber; Jose S R Oliveira; Celso A Rodrigues; Celso F H Granato
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-06-02       Impact factor: 2.743

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.